<DOC>
	<DOCNO>NCT00954512</DOCNO>
	<brief_summary>This Phase 1B/2 , non-randomized , dose-escalation , multicenter , open-label study design evaluate safety tolerability robatumumab ( SCH 717454 , MK-7454 ) combination standard treatment participant advance solid tumor conduct conformance Good Clinical Practices . Six different treatment regimen investigate combination robatumumab . The study divide two part . Part 1 consist initial safety evaluation dose-finding robatumumab combination treatment regimen . Part 2 consist expansion robatumumab regimen newly establish dose level , good define safety , tolerability , initial efficacy specific target population .</brief_summary>
	<brief_title>Study Robatumumab ( SCH 717454 , MK-7454 ) Combination With Different Treatment Regimens Participants With Advanced Solid Tumors ( P04722 , MK-7454-004 )</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Be willing able provide write informed consent study . Be Â±18 year age either sex race/ethnicity ; Part 1 : Have histologically cytologically confirm advanced malignant solid tumor ; Part 2 : Have histologically cytologically confirm , measurable disease ( define Response Evaluation Criteria Solid Tumors [ RECIST ] ) , advance , malignant solid tumor . Have Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 . Have adequate organ function within 3 week prior first study drug administration . Not know treat untreated leptomeningeal metastasis metastatic central nervous system lesion . Not history another malignancy Not receive prior therapy antiinsulinlike growth factor receptor 1 ( antiIGF1R ) monoclonal antibody . Not receive radiation therapy within 2 week prior first study drug administration . Not receive radiation therapy &gt; 25 % his/her total bone marrow his/her lifetime . Not undergone major surgery within 3 week prior first study drug administration . Not know human immunodeficiency virus ( HIV ) infection know HIVrelated malignancy . Not know active hepatitis B C. Not serious uncontrolled infection . Not uncontrolled diabetes mellitus . Not follow within 6 month prior first study drug administration : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , clinically significant cardiac dysrhythmia clinically significant electrocardiogram ( ECG ) abnormality , cerebrovascular accident transient ischemic attack , seizure disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Antibodies , neoplasm</keyword>
</DOC>